An Open-Label, Multicenter, Single-Arm, Phase-2 Study of Single-Agent Mosunetuzumab (BTCT4465A, RO7030816) for the Treatment of Patients with Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy

14615MSK22-100-NCT05389293OpenAn Open-Label, Multicenter, Single-Arm, Phase-2 Study of Single-Agent Mosunetuzumab (BTCT4465A, RO7030816) for the Treatment of Patients with Newly Diagnosed Follicular Lymphoma in Need of Systemic TherapyNCT05389293Externally Peer-ReviewedAdultTreatmentIINon-Hodgkin LymphomaRoswarski, JosephGeorgetown University Medical Center : Ayodeji Olukoya, Ayodeji Olukoya; Lombardi Comprehensive Cancer Center : Ayodeji Olukoya, Ayodeji OlukoyaLymphomaOncology GroupLombardi Comprehensive Cancer Center (LCCC)16185Ayodeji OlukoyaAyodeji Olukoyaaoo42@georgetown.edu16185Ayodeji OlukoyaAyodeji Olukoyaaoo42@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>